BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 30 2024 - 4:15PM
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the
“Company”) (NASDAQ:BRTX
), a clinical stage company
focused on stem cell-based therapies, today announced that it will
release its first quarter 2024 financial results after market close
on Tuesday, May 14, 2024.
"I look forward to providing more detail on our
exciting recently announced transformative commercial partnership
with Cartessa, as well as discussing the meaningful progress we are
making with our clinical and preclinical development programs,
during this, our first-ever quarterly conference call,” said Lance
Alstodt, BioRestorative’s CEO.
Following the announcement, BioRestorative
management will host its inaugural quarterly conference call to
review the financial results and provide a business update.
First Quarter 2024 Results Conference
Call Details:
Date: |
Tuesday, May 14, 2024 |
Time: |
4:30 p.m. ET |
Domestic: |
1-888-506-0062 |
International: |
1-973-528-0011 |
Access Code: |
357232 |
Participants are asked to dial in approximately
10 minutes before the conference call is scheduled to begin. The
call can also be accessed via webcast on the Company's website at
https://www.biorestorative.com/investor-relations under “Events.”
The webcast will be archived and accessible for approximately 90
days.
About BioRestorative Therapies,
Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have commenced a
Phase 2 clinical trial using BRTX-100 to treat chronic
lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and
diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:
Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From May 2023 to May 2024